autologous dendritic cell therapy + peginterferon

**Autologous dendritic cell therapy + peginterferon** is a combination immunotherapy approach designed for cancer treatment. Autologous dendritic cell therapy involves extracting dendritic cells from a patient, loading them ex vivo with tumor antigens (often derived from the patient’s own tumor), and re-administering them to induce a targeted anti-tumor immune response. Peginterferon refers to a pegylated form of interferon alpha, a cytokine with immunomodulatory and antiproliferative effects. The combination aims to enhance the priming and activation of tumor-specific T cells by providing both antigen presentation (via dendritic cells) and immune stimulation (via peginterferon). This strategy has been evaluated primarily in solid tumors and hematologic malignancies, with dendritic cell therapy showing ability to trigger antigen-specific T cell responses and interferon providing additional immunostimulation and tumor inhibition[1][3][4][5][6].